{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:26:31Z","timestamp":1790900791788,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-026-04743-7","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:36:20Z","timestamp":1773830180000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tislelizumab-induced Vogt-Koyanagi-Harada-like uveitis: a case report"],"prefix":"10.1186","volume":"26","author":[{"given":"Yunyun","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"4743_CR1","doi-asserted-by":"publisher","first-page":"e002456","DOI":"10.1136\/bmjophth-2025-002456","volume":"10","author":"S Xu","year":"2025","unstructured":"Xu S, Song Z, Li Y, Bai J, Wang D, Wang E, et al. Drug-induced immune-mediated uveitis: a real-world pharmacovigilance analysis using FAERS and JADER databases. BMJ Open Ophthalmol. 2025;10:e002456. https:\/\/doi.org\/10.1136\/bmjophth-2025-002456.","journal-title":"BMJ Open Ophthalmol"},{"key":"4743_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000496682","volume":"10","author":"S Obata","year":"2019","unstructured":"Obata S, Saishin Y, Teramura K, Ohji M. Vogt-Koyanagi-Harada Disease-Like Uveitis during Nivolumab (Anti-PD-1 Antibody) Treatment for Metastatic Cutaneous Malignant Melanoma. Case Rep Ophthalmol. 2019;10:67\u201374. https:\/\/doi.org\/10.1159\/000496682.","journal-title":"Case Rep Ophthalmol"},{"key":"4743_CR3","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12886-024-03484-9","volume":"24","author":"J-N Wang","year":"2024","unstructured":"Wang J-N, Zhang Y, Huang C-Y, Li K, Yu X-B. Development of Vogt-Koyanagi-Harada disease-like uveitis during treatment by anti-programmed death-1 antibody: a case report. BMC Ophthalmol. 2024;24:240. https:\/\/doi.org\/10.1186\/s12886-024-03484-9.","journal-title":"BMC Ophthalmol"},{"key":"4743_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40265-020-01286-z","volume":"80","author":"A Lee","year":"2020","unstructured":"Lee A, Keam SJ, Tislelizumab. First Approval Drugs. 2020;80:617\u201324. https:\/\/doi.org\/10.1007\/s40265-020-01286-z.","journal-title":"First Approval Drugs"},{"key":"4743_CR5","doi-asserted-by":"publisher","first-page":"e002119","DOI":"10.1136\/jitc-2020-002119","volume":"9","author":"L Young","year":"2021","unstructured":"Young L, Finnigan S, Streicher H, Chen HX, Murray J, Sen HN, et al. Ocular adverse events in PD-1 and PD-L1 inhibitors. J Immunother Cancer. 2021;9:e002119. https:\/\/doi.org\/10.1136\/jitc-2020-002119.","journal-title":"J Immunother Cancer"},{"key":"4743_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ajo.2019.02.012","volume":"202","author":"K Bitton","year":"2019","unstructured":"Bitton K, Michot J-M, Barreau E, Lambotte O, Haigh O, Marabelle A, et al. Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1\/PD-L1 Anticancer Immunotherapy. Am J Ophthalmol. 2019;202:109\u201317. https:\/\/doi.org\/10.1016\/j.ajo.2019.02.012.","journal-title":"Am J Ophthalmol"},{"key":"4743_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1590\/s0004-27492009000300028","volume":"72","author":"FM Damico","year":"2009","unstructured":"Damico FM, Bezerra FT, da Silva GC, Gasparin F, Yamamoto JH. New insights into Vogt-Koyanagi-Harada disease. Arq Bras Oftalmol. 2009;72:413\u201320. https:\/\/doi.org\/10.1590\/s0004-27492009000300028.","journal-title":"Arq Bras Oftalmol"},{"key":"4743_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12348-022-00293-3","volume":"12","author":"CA Urzua","year":"2022","unstructured":"Urzua CA, Herbort CP, Takeuchi M, Schlaen A, Concha-Del-Rio LE, Usui Y, et al. Vogt-Koyanagi-Harada disease: the step-by-step approach to a better understanding of clinicopathology, immunopathology, diagnosis, and management: a brief review. J Ophthalmic Inflamm Infect. 2022;12:17. https:\/\/doi.org\/10.1186\/s12348-022-00293-3.","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"4743_CR9","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/s41433-025-03720-6","volume":"39","author":"CA Urzua","year":"2025","unstructured":"Urzua CA, Olate-Perez A, Anguita R, Schlaen A, Munk MR, Carre\u00f1o E, et al. Vogt-Koyanagi-Harada-like disease secondary to anticancer treatment: a multicentre case series. Eye Lond Engl. 2025;39:1751\u20137. https:\/\/doi.org\/10.1038\/s41433-025-03720-6.","journal-title":"Eye Lond Engl"},{"key":"4743_CR10","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3892\/mmr.2021.12442","volume":"24","author":"C-C Hsiao","year":"2021","unstructured":"Hsiao C-C, Chang Y-C, Hsiao Y-T, Chen P-H, Hsieh M-C, Wu W-C, et al. Triamcinolone acetonide modulates TGF\u2013\u03b22\u2013induced angiogenic and tissue\u2013remodeling effects in cultured human retinal pigment epithelial cells. Mol Med Rep. 2021;24:802. https:\/\/doi.org\/10.3892\/mmr.2021.12442.","journal-title":"Mol Med Rep"},{"key":"4743_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1089\/jop.2009.0060","volume":"25","author":"W Huang","year":"2009","unstructured":"Huang W, Yang AH, Matsumoto D, Collette W, Marroquin L, Ko M, et al. PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. 2009;25:519\u201330. https:\/\/doi.org\/10.1089\/jop.2009.0060.","journal-title":"J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther"},{"key":"4743_CR12","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/s0002-9394(14)70645-2","volume":"121","author":"Y Kawano","year":"1996","unstructured":"Kawano Y, Tawara A, Nishioka Y, Suyama Y, Sakamoto H, Inomata H. Ultrasound biomicroscopic analysis of transient shallow anterior chamber in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 1996;121:720\u20133. https:\/\/doi.org\/10.1016\/s0002-9394(14)70645-2.","journal-title":"Am J Ophthalmol"},{"key":"4743_CR13","unstructured":"Ocular. and extraocular inflammation induced by immunization of tyrosinase related protein 1 and 2 in Lewis rats - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/10995557\/. Accessed 27 Feb 2026."},{"key":"4743_CR14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/s0002-9394(14)71973-7","volume":"122","author":"T Gohdo","year":"1996","unstructured":"Gohdo T, Tsukahara S. Ultrasound Biomicroscopy of shallow anterior chamber in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 1996;122:112\u20134. https:\/\/doi.org\/10.1016\/s0002-9394(14)71973-7.","journal-title":"Am J Ophthalmol"},{"key":"4743_CR15","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.ajo.2006.01.017","volume":"141","author":"H Keino","year":"2006","unstructured":"Keino H, Goto H, Mori H, Iwasaki T, Usui M. Association between severity of inflammation in CNS and development of sunset glow fundus in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2006;141:1140\u20132. https:\/\/doi.org\/10.1016\/j.ajo.2006.01.017.","journal-title":"Am J Ophthalmol"},{"key":"4743_CR16","first-page":"3890","volume":"35","author":"SM Islam","year":"1994","unstructured":"Islam SM, Numaga J, Fujino Y, Hirata R, Matsuki K, Maeda H, et al. HLA class II genes in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 1994;35:3890\u20136.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4743_CR17","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12886-020-01519-5","volume":"20","author":"R Kikuchi","year":"2020","unstructured":"Kikuchi R, Kawagoe T, Hotta K. Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report. BMC Ophthalmol. 2020;20:252. https:\/\/doi.org\/10.1186\/s12886-020-01519-5.","journal-title":"BMC Ophthalmol"},{"key":"4743_CR18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3390\/vaccines8040575","volume":"8","author":"M Morgado","year":"2020","unstructured":"Morgado M, Pl\u00e1cido A, Morgado S, Roque F. Management of the Adverse Effects of Immune Checkpoint Inhibitors. Vaccines. 2020;8:575. https:\/\/doi.org\/10.3390\/vaccines8040575.","journal-title":"Vaccines"},{"key":"4743_CR19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/JOP.18.00005","volume":"14","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Thompson JA. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2018;14:247\u20139. https:\/\/doi.org\/10.1200\/JOP.18.00005.","journal-title":"J Oncol Pract"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-04743-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04743-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04743-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T01:51:50Z","timestamp":1777254710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-04743-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4743"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-04743-7","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for this case report in accordance with the local ethical review regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient provided written informed consent for publication of this case report and accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"214"}}